Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2015 Mar;67(3):857-8.
doi: 10.1002/art.38992.

Half-life and safety of canakinumab in pediatric patients: comment on the article by Ilowite et Al

Hermine Brunner  1 , Kathleen Graham Lomax, Stephane Levy
Affiliations
Comment

Half-life and safety of canakinumab in pediatric patients: comment on the article by Ilowite et Al

Hermine Brunner et al. Arthritis Rheumatol. 2015 Mar.
No abstract available

PubMed Disclaimer

Comment in

  • Reply: To PMID 24839206.
    Ilowite NT; RAPPORT Investigators. Ilowite NT, et al. Arthritis Rheumatol. 2015 Mar;67(3):858. doi: 10.1002/art.38991. Arthritis Rheumatol. 2015. PMID: 25511916 No abstract available.

Comment on

References

    1. Ilowite NT, Prather K, Lokhnygina Y, Schanberg LE, Elder M, Milojevic D, et al. Randomized, double-blind, placebo-controlled trial of the efficacy and safety of rilonacept in the treatment of systemic juvenile idiopathic arthritis. Arthritis Rheumatol. 2014;66:2570–9. - PMC - PubMed
    1. Ilaris (canakinumab) prescribing information. East Hanover (NJ): Novartis Pharmaceuticals; 2014.
    1. Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum. 1997;40:1202–9. - PubMed
    1. Ruperto N, Brunner HI, Quartier P, Constantin T, Wulffraat N, Horneff G, et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367:2396–406. - PubMed
    1. Novartis Pharmaceuticals and Pediatric Rheumatology International Trials Organization. Flare prevention study of canakinumab in patients with active systemic juvenile idiopathic arthritis (SJIA) (β-SPECIFIC 2). URL: http://www.clinicaltrials.gov/ct2/show/study/NCT00889863.

Substances